IBD and Pregnancy: A Comprehensive Guide for Expectant Mothers
"Navigating treatment options, managing symptoms, and ensuring a healthy pregnancy with inflammatory bowel disease."
Inflammatory bowel disease (IBD) affects many women during their childbearing years. Balancing IBD treatment with the health of both mother and fetus requires careful consideration. Untreated IBD flare-ups during pregnancy can lead to serious complications, making effective management essential.
Many patients and even some physicians lack full understanding about the safety of IBD medications during pregnancy. This can lead to unnecessary discontinuation of vital treatments. However, controlling IBD activity is the single most important factor in ensuring a positive pregnancy outcome.
This guide provides a comprehensive overview of managing IBD during pregnancy. It covers everything from understanding the clinical manifestations and safely diagnosing IBD, to exploring treatment options and nutritional support, empowering you to make informed decisions for a healthy pregnancy.
Evidence Gaps and Patient Impact
Pregnancy can be complex and risk-filled for women with inflammatory bowel disease (IBD). High-quality studies remain lacking, including limited data on medications approved to treat IBD during pregnancy. This limited knowledge can affect pregnancy rates, medication adherence, and outcomes. The 2025 consensus statement emphasizes individualized treatment plans, shared decision-making, and education to support adherence.
Individualized Care and Uncertainty
Care for IBD during pregnancy generally requires individualized decisions made jointly by patients and healthcare professionals. Treatment choices must weigh maternal disease control against potential fetal risks, but the evidence base remains incomplete. Because pregnancy-specific data are limited, recommendations may need to be adapted to each patient's disease history, treatment, and pregnancy circumstances.
From Limited Evidence to Consensus Guidance
The 2025 global consensus statement reflects a major effort to organize guidance for pregnancy in women with IBD. Its development responds to persistent gaps in high-quality studies and limited information about IBD medications during pregnancy. The statement also recognizes that uncertainty has consequences for pregnancy rates, medication adherence, and outcomes. Together, these developments mark a shift toward more structured, evidence-informed pregnancy care.
Understanding IBD Symptoms and Pregnancy
The symptoms of IBD during pregnancy mirror those experienced at other times. While most pregnancies in women with IBD are classified as high-risk, many proceed without significant complications. However, clinical exacerbations can occur, particularly in the first trimester, affecting up to a third of pregnant women with IBD.
- Increased risk of spontaneous abortions.
- Premature deliveries.
- Babies born with low birth weight and/or small for gestational age.
- Increased need for surgical deliveries.
Recent Evidence and Clinical Updates
The March 2024 Lancet Seminar reviews new therapies and research evaluating pregnancy outcomes in people with IBD. It is intended to update care providers on issues relevant to achieving optimal pregnancy outcomes. A separate 2026 study collected retrospective data on IBD history, disease activity, treatment, hospital-admission reasons, investigations, and pregnancy outcomes. Together, these sources show current research combining broad clinical reviews with real-world pregnancy data.
The Cost of Active Disease
Evidence reviewed across pregnancy and IBD sources identifies active disease as a central weakness in pregnancy management. One overview reports that disease activity is the most significant risk factor for pregnancy complications and that patients with active disease may be up to three times or more likely to experience a complication than those without active disease. A 2025 update likewise associates active IBD during pregnancy with adverse maternal and fetal outcomes. These findings support achieving remission before conception and monitoring inflammation throughout pregnancy.
Balancing Competing Risks
Comparing approaches to pregnancy in IBD requires balancing disease control, treatment decisions, and pregnancy-related concerns. The available evidence does not support treating all patients identically because risks vary with disease activity, treatment, and the stage of care. A cautious comparison therefore favors individualized monitoring and decisions rather than a single universal strategy. The limitations of existing studies also make definitive comparisons difficult.
Key Takeaways for a Healthy Pregnancy with IBD
The primary goal is to manage IBD effectively to minimize risks and improve pregnancy outcomes. Don't let fear of medication side effects lead to undertreatment; work with your doctors to find safe and effective options.
Evidence-Informed Shared Decisions
Current expert guidance aims to help clinicians make informed decisions that protect maternal health while minimizing fetal risks. This approach recognizes that pregnancy management in IBD involves balancing competing interests rather than pursuing one outcome in isolation. Practical care therefore depends on applying current evidence alongside clinical judgment and the patient's circumstances.
Noninvasive Monitoring Advances
Recent advances in diagnostics, therapeutics, and preventative care continue to shape IBD management during pregnancy. The increasing use of noninvasive disease-monitoring tools, including intestinal ultrasound (IUS), may enable point-of-care assessment early in pregnancy. The cited update describes IUS as supporting earlier treatment decisions when inflammation is detected. These developments point toward more responsive, pregnancy-specific monitoring.
Pregnancy Beyond Disease Control
IBD affects women across the full reproductive journey, from decisions about conception to carrying a pregnancy. Broader concerns include whether the disease may be passed to children, fetal outcomes, and the effects of pregnancy on the disease process itself. These interconnected issues show why pregnancy care must address more than medication selection or symptom control. Support for reproductive decision-making is therefore part of the wider management challenge.
Balancing Maternal and Fetal Needs
Real-world management of IBD in pregnancy must balance benefits and risks for both the mother and fetus. A 2026 epidemiology and treatment study examines pregnancy incidence and treatment patterns among women with IBD, while a 2024 cohort study assesses pregnancy complications according to disease activity and evaluates the standard of care. These studies place individual experiences within broader patterns of treatment and outcomes. They also reinforce the importance of considering disease activity when interpreting pregnancy complications.
Maintaining remission is key. Active IBD poses a greater threat to both mother and baby than most medications when appropriately managed.
With careful planning and close medical supervision, women with IBD can have healthy pregnancies and deliver healthy babies. Stay informed, advocate for your health, and prioritize disease control.